Date: August 24, 2021
Time: 2:00pm GMT, 4:00Pm CEST
Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) are found in high global seroprevalence. Infections usually are asymptomatic or manifest as mild or subclinical disease in immunocompetent individuals and establish life-long latency without causing serious health problems. However, in immunocompromised patients such as transplant recipients, reactivation of latent virus can result in severe disease. Patient monitoring, including quantitative nucleic acid testing (QNAT), may play an important role in patient management. Alinity m CMV and Alinity m EBV assays are quantitative in vitro polymerase chain reaction assays with a dual-target design to aid in redundancy in detection. This webinar will discuss the design and performance of the Alinity m CMV and Alinity m EBV assays.
- Review CMV & EBV Disease and Current Challenges
- Review the Alinity m CMV & EBV Assay Design
- Review Alinity m CMV & EBV Assay Clinical Performance
Alinity m CMV and Alinity m EBV assays are CE-marked. Check with your local representative for availability in specific markets.
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.